CDK4 and liposarcoma: As we will discuss, the success of CDK4/6 inhibitors in patients with dedifferentiated liposarcoma has validated CDK4 gene amplification as a driver mutation in this subtype and is leading the way for similar trials in additional soft tissue sarcoma subtypes.